Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study.

Abstract

BACKGROUND:

Studies indicate that myeloperoxidase (MPO) is associated with disease progression and severity in heart failure (HF), while it may provide a mechanistic link between inflammation and adverse cardiac remodeling. The mechanisms that regulate MPO are unclear, while it is unknown whether specific treatments such as HMG-CoA reductase inhibitors and xanthine oxidase inhibitors may modify MPO. Therefore in the present study we examined the effects of rosuvastatin and allopurinol on MPO levels in patients HF.

METHODS:

Sixty clinically stable patients with systolic HF were randomized to receive rosuvastatin 10mg/day, allopurinol 300mg/day or placebo and followed up for 1 month. Plasma levels of MPO and serum levels of soluble CD40 ligand, interleukin-6, and oxidized LDL were determined using ELISA. All measurements were made before and after 1-month treatment.

RESULTS:

Rosuvastatin significantly reduced plasma levels of MPO (p=0.003), which remained unchanged in the other groups. Furthermore, the change of MPO levels in the rosuvastatin-treated group was significantly different compared with the other groups (p<0.05). Rosuvastatin administration also led to a significant decrease in oxidized LDL (p=0.009), while the other inflammatory markers remained unchanged in all groups. In the total population, a significant correlation was observed between the baseline levels of MPO and hsCRP (r=0.275, p=0.027), fibrinogen (r=0.278, p=0.025), and sCD40L (r=0.288, p=0.021).

CONCLUSIONS:

Short-term treatment with rosuvastatin regulates inflammatory process in patients with heart failure by significantly reducing plasma levels of MPO. This finding reveals a novel pleiotropic effect of statins in patients with heart failure, and provides further insights into the pathophysiological mechanisms of MPO in heart failure.

• Authors: Ioannis Andreou, Dimitris Tousoulis, Antigoni Miliou, Costas Tentolouris, Kostas Zisimos, Panagiota Gounari, Gerasimos Siasos, Nikos Papageorgiou, Christos A Papadimitriou, Meletios-Athanasios Dimopoulos, Christodoulos Stefanadis
• Journal: Atherosclerosis (Atherosclerosis) Vol. 210 Issue 1 Pg. 194-8 (May 2010) ISSN: 1879-1484 [Electronic] Ireland
• PMID: 19962701 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Biomarkers
• Cholesterol, LDL
• Fluorobenzenes
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Pyrimidines
• Sulfonamides
• Triglycerides
• Allopurinol
• Rosuvastatin Calcium
• Cholesterol
• Peroxidase

Topics

• Aged
• Allopurinol (pharmacology, therapeutic use)
• Biomarkers (blood)
• Cholesterol (blood)
• Cholesterol, LDL (blood)
• Chronic Disease
• Female
• Fluorobenzenes (pharmacology, therapeutic use)
• Heart Failure (blood, drug therapy)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (pharmacology, therapeutic use)
• Inflammation (drug therapy)
• Male
• Peroxidase (blood)
• Pyrimidines (pharmacology, therapeutic use)
• Rosuvastatin Calcium
• Sulfonamides (pharmacology, therapeutic use)
• Triglycerides (blood)